dpp-4 inhibitor and glp-1 receptor agonist combination versus kidney and cardiovascular outcomes in clinical practice in type-2 diabetes The Role of DPP-4 Inhibitors
Description
If you have undergone gallbladder surgery or suffered from severe gastroparesis after using these medications, you may have grounds for a GLP-1 drugs personal injury claim
The hypothesis was that tirzepatide would reduce LV mass and epicardial adipose tissue (EAT) in these patients
Together, these inputs help preserve lean mass during periods of weight change
Intermittent fasting and hormonal regulation: Pathways to improved metabolic health
The emergence of sodium-glucose cotransporter 2 (SGLT2) inhibitors and glucagon-like peptide-1 (GLP-1) receptor agonists has reshaped DKD management
